New cocktail of cancer drugs tested for safety
NCT ID NCT01187199
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 28 times
Summary
This early-stage trial aims to find the safest highest dose of a two-drug combination (bevacizumab and temsirolimus) when given with one of three other drugs (carboplatin, paclitaxel, or sorafenib) for people with advanced cancer that hasn't responded to standard treatments. About 278 participants will be enrolled to monitor side effects and see if the combinations help control the disease. The goal is to manage the cancer, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.